Having trouble accessing articles? Reset your cache.

Imetelstat: Updated Phase II data

Updated data from a pre-specified subgroup of 20 NSCLC patients whose tumors had short telomeres at baseline as measured by telomeric fluorescence in situ hybridization (FISH) in the open-label, U.S. Phase II B012 trial in 116 patients showed that maintenance therapy with imetelstat did not increase

Read the full 466 word article

User Sign In

Trial Subscription

Get a two-week free trial subscription to BioCentury


Article Purchase

This article may not be distributed to non-subscribers